Source: Canadian Agency for Drugs and Technologies in Health (CADTH)
Area: News
This Rapid Response Report from the Canadian Agency for Drugs and Technologies in Health (CADTH) discusses the available evidence regarding the comparative clinical efficacy and safety of short term (<4 weeks) use of Suboxone® (buprenorphine/naloxone) compared with other opioid detoxification agents such as buprenorphine alone, methadone, and clonidine, and placebo.
 
The results of their limited literature search are described and summarised in the report (see link below); the main conclusions drawn were as follows:
 
. The evidence comparing the clinical effectiveness of short term Suboxone® detoxification with other alternative medications in the treatment of patients with opioid…